Phase 3 Development and Current Evidence Level Retatrutide is in phase 3 development for several metabolic indications, including obesity and type 2 diabetes, while published phase 2 trials and 2026 phase 3 reports provide the main current human evidence [2], [7], [8]
Perhaps more importantly for weight management, it slows down gastric emptying, which is the speed at which food leaves your stomach
This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access 269,00 per year only 22,42 per issue Rent or buy this article Prices vary by article type from$1.95 to$39.95 Prices may be subject to local taxes which are calculated during checkout Subjects References McMurray, J
Great product and company Very easy process and about the best price I could find
Purification of nucleic acids by extraction with phenol:chloroform